Premium
Serum glutathione‐s‐transferase‐π as a tumor marker for gastrointestinal malignancies
Author(s) -
Niitsu Yoshiro,
Takahashi Yasuo,
Saito Tadanori,
Hirata Yasuji,
Arisato Nobuko,
Maruyama Hiroshi,
Kohgo Yutaka,
Listowsky Irving
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890115)63:2<317::aid-cncr2820630219>3.0.co;2-p
Subject(s) - medicine , immunoradiometric assay , gastroenterology , tumor marker , cirrhosis , cancer , gastrointestinal cancer , hepatocellular carcinoma , gastrointestinal tract , stomach , glutathione , stage (stratigraphy) , pathology , colorectal cancer , radioimmunoassay , biology , paleontology , biochemistry , enzyme
A glutathione‐S‐transferase‐π (GST‐π) immunoradiometric assay was devised as a potential marker for serodiagnosis of malignant disease. Elevated serum GST‐π levels were observed in patients with various gastrointestinal malignancies including gastric, esophageal, colonic, pancreatic, hepatocellular, and biliary tract cancers. Patients with benign gastrointestinal diseases had normal GST‐π, but some patients with chronic hepatitis and cirrhosis had slightly elevated levels. Over 80% of patients with Stage III or IV gastric cancer and even about 50% of those with Stage I and II had elevated serum GST‐π. After surgery serum GST‐π levels returned to normal. Resected stomach cancers were immunohistochemically positive for GST‐π. During chemotherapy of colonic, gastric, and hepatocellular cancers with a series of different drugs, GST‐π changed in a biphasic manner; increases during initial phases of therapy may reflect acquisition of drug resistance by the tumor. In general, serum GST‐π assays provide a sensitive and reliable marker for gastrointestinal malignancies.